Commercial Platform

We have developed a profitable Commercial Platform, encompassing our strategically important Prescription Drugs business and our Consumer Health business. The Commercial Platform has grown strongly and provided an important source of funding for our Innovation Platform and the infrastructure and know-how in operating and marketing pharmaceutical products in China.

Our Prescription Drugs business, conducted through our joint ventures Shanghai Hutchison Pharmaceuticals and Hutchison Sinopharm, in which we nominate management and run the day-to-day operations. It has a commercial network of about 2,500 medical sales representatives, covering over 24,900 hospitals in over 320 cities and towns in China.

The other element of our Commercial Platform is our Consumer Health business which focuses primarily on the manufacture, marketing and distribution of over-the-counter pharmaceutical products and other natural and organic consumer products in China. Our Consumer Health Products include Hutchison Baiyunshan, Hutchison Hain Organic, Hutchison Healthcare and Hutchison Consumer Products.

It is our strategy to combine the marketing and sales experience and hospital access gained from our Commercial Platform’s operations with our growing dedicated oncology-focused sales team to support the launch of products from our Innovation Platform if and when they are approved for use in China.

Outside of China, we intend to commercialize our products, if approved, in the United States, Europe and other major markets on our own and/or through partnerships with leading biopharmaceutical companies.

A profitable & high growth platform to launch our new drug innovations.

For more information on recent developments, please refer to the Full Year Results Presentation and the 2018 Annual Report.